Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan joint venture

Executive Summary

Firm made an agreemtn-in-principle to form joint venture with Product Resources Internatl. for development of products utilizing Elan's PharmaZome technology and PRI's Edible Whip suspension drug delivery system. Elan said it also entered an agreement-in-principle with Chemie Linz AG for joint ventures in West Germany and France in which Elan will supply products and Chemie Linz will supply marketing forces.

You may also be interested in...



Biden Extends Helping Hand To Small US Manufacturers, Vendors With ‘Made In America’ EO

The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.

Warning Letter Roundup & Recap – 26 January 2021

No device-related warning letters were released by the US FDA the week of 26 January.

EU Crunch Time For Two Drugs That Lost Their Fast-Track Status

Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel